Company MedinCell S.A.

MEDCL

FR0004065605

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-01-16 am EST			5-day change	1st Jan Change
28.22 ^EUR	+4.99%		+10.75%	+11.98%

Dec. 10	Medincell Narrows Operating Loss in First Half
Dec. 10	MedinCell Says Partner Filed US FDA Application for Once-monthly Schizophrenia Treatment	MT

Business description: MedinCell S.A.

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM).

As of March 31, 2025, the company had a portfolio of 2 products in phase III clinical development and 3 products in preclinical development.

Number of employees: 145

Sales by Activity: MedinCell S.A.

Fiscal Period: March	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Conducting Research and Development on Biodegradable Polymer-Based Processes	11.78M	4.09M	13.66M	11.94M	27.73M

See all business segments

Geographical breakdown of sales: MedinCell S.A.

Fiscal Period: March	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Germany	-	368K	1.98M	-	-
Others	1.11M	-	2.57M	1.35M	-
Switzerland	-	1.31M	-	632K	-
United States	2.54M	2.41M	2.18M	1.63M	-
Israel	4.35M	-	3.16M	5.42M	-
France	200K	-	-	-	-

See all geographic segments

Executive Committee: MedinCell S.A.

Manager	Title	Age	Since
Christophe Douat CEO	Chief Executive Officer	62	2003-01-08
Stéphane Postic DFI	Director of Finance/CFO	52	2023-08-31
Richard Malamut CTO	Chief Tech/Sci/R&D Officer	67	2022-05-08
Adolfo Lopez-Noriega CTO	Chief Tech/Sci/R&D Officer	-	2016-12-31
Sébastien Magnat COO	Chief Operating Officer	-	2019-03-31

See MEDINCELL S.A. governance

Composition of the Board of Directors: MedinCell S.A.

Director	Title	Age	Since
Christophe Douat BRD	Director/Board Member	62	2003-01-08
Philippe Guy CHM	Chairman	-	2024-03-12
Virginie Lleu BRD	Director/Board Member	-	2016-05-24
Elisabeth Kogan BRD	Director/Board Member	-	2020-12-14
Tone Kvåle BRD	Director/Board Member	57	2022-06-12
Pascal Touchon BRD	Director/Board Member	63	2025-02-28
Sharon Mates BRD	Director/Board Member	73	2025-09-10
Charles Kunsch BRD	Director/Board Member	-	2025-09-10

Composition of the Board of Directors

Shareholders: MedinCell S.A.

Name	Equities	%	Valuation
Mirova SA (Investment Management) 7.373 %	2,458,744	7.373 %	73 M €
Dassault Family 5.009 %	1,670,426	5.009 %	49 M €
Anh Nguyen 4.367 %	1,456,343	4.367 %	43 M €
Adage Capital Management LP 3.777 %	1,259,424	3.777 %	37 M €
BNP Paribas Développement SA 3.271 %	1,090,688	3.271 %	32 M €

List of MEDINCELL S.A. shareholders

Holdings: MedinCell S.A.

Name	Equities	%	Valuation
MEDINCELL S.A. 0.01%	5,000	0.01%	147 981 $

Company details: MedinCell S.A.

MedinCell SA

3, rue des Frères Lumière

34830, Jacou

+33 4 67 02 13 67

http://www.medincell.com

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MEDINCELL S.A.	+4.99%	+10.75%	+73.13%	+264.60%	1.08B
ELI LILLY AND COMPANY	+0.53%	-2.37%	+43.09%	+190.27%	930B
JOHNSON & JOHNSON	-0.41%	+6.98%	+48.72%	+26.86%	527B
ABBVIE INC.	-0.31%	-2.60%	+24.94%	+40.25%	379B
ROCHE HOLDING AG	+0.93%	+2.38%	+31.46%	+18.47%	371B
ASTRAZENECA PLC	+0.19%	-1.15%	+28.47%	+21.14%	292B
NOVARTIS AG	+0.98%	+1.37%	+29.42%	+35.03%	276B
MERCK & CO., INC.	-1.93%	-1.54%	+11.14%	-1.47%	270B
NOVO NORDISK A/S	+6.49%	+1.95%	-32.44%	-18.44%	268B
AMGEN INC.	+0.12%	+1.32%	+21.43%	+22.64%	178B
Average	+1.16%	+1.71%	+27.94%	+59.94%	349.2B
Weighted average by Cap.	+0.59%	+0.51%	+29.06%	+65.29%